Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Wednesday.

Other research analysts have also recently issued research reports about the stock. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Finally, DA Davidson restated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $85.25.

Prestige Consumer Healthcare Price Performance

NYSE:PBH traded down $1.60 during mid-day trading on Wednesday, reaching $78.79. The stock had a trading volume of 341,900 shares, compared to its average volume of 252,632. Prestige Consumer Healthcare has a 12 month low of $57.95 and a 12 month high of $86.36. The stock has a market capitalization of $3.89 billion, a PE ratio of 19.17, a P/E/G ratio of 2.32 and a beta of 0.49. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The stock has a 50-day simple moving average of $78.86 and a two-hundred day simple moving average of $72.90.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. During the same quarter last year, the company posted $1.07 EPS. The company’s revenue for the quarter was down .9% compared to the same quarter last year. On average, equities analysts anticipate that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

Insider Activity

In other news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares in the company, valued at approximately $1,505,930. The trade was a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Mary Beth Fritz sold 9,885 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the sale, the senior vice president now directly owns 18,835 shares in the company, valued at approximately $1,543,904.95. This represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 over the last quarter. 1.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PBH. Quest Partners LLC increased its stake in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after buying an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC increased its position in Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares during the period. Huntington National Bank raised its holdings in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares during the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Prestige Consumer Healthcare by 106.9% in the 2nd quarter. Blue Trust Inc. now owns 867 shares of the company’s stock worth $63,000 after purchasing an additional 448 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.